Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merit Cudkowicz
Jeremy Shefner

Showing results (71-80 of 154) with videos related to

Pageof 16
Sort By:
Annals of Neurology|September 17, 2014
Quantifying disease progression in amyotrophic lateral sclerosisNeil G Simon, Martin R Turner, Steve Vucic, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 1, 2022
Automated semantic relevance as an indicator of cognitive decline: Out-of-sample validation on a large-scale longitudinal datasetGabriela Stegmann, Shira Hahn, Samarth Bhandari, et al.
Muscle & Nerve|October 18, 2019
Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19)Jeremy Shefner, Terry Heiman-Patterson, Erik P Pioro, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 16, 2014
Seeking a measure of clinically meaningful change in ALSMartin McElhiney, Judith G Rabkin, Raymond Goetz, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 18, 2015
Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALSRobert G Miller, Gilbert Block, Jonathan S Katz, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 27, 2024
Automated speech analytics in ALS: higher sensitivity of digital articulatory precision over the ALSFRS-RGabriela Stegmann, Chelsea Krantsevich, Julie Liss, et al.
Annals of Neurology|December 19, 2023
Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and PracticeMichael Benatar, Lyle W Ostrow, Joseph W Lewcock, et al.
BMC Neurology|May 31, 2019
Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALSAnne Marie Wills, Jamie Garry, Jane Hubbard, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|December 8, 2009
A phase II trial of talampanel in subjects with amyotrophic lateral sclerosisRobert M Pascuzzi, Jeremy Shefner, Amy S Chappell, et al.
Pageof 16

Showing results (71-80 of 154) with videos related to

Sort By:
Pageof 16
Annals of Neurology|September 17, 2014
Quantifying disease progression in amyotrophic lateral sclerosisNeil G Simon, Martin R Turner, Steve Vucic, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 1, 2022
Automated semantic relevance as an indicator of cognitive decline: Out-of-sample validation on a large-scale longitudinal datasetGabriela Stegmann, Shira Hahn, Samarth Bhandari, et al.
Muscle & Nerve|October 18, 2019
Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19)Jeremy Shefner, Terry Heiman-Patterson, Erik P Pioro, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 16, 2014
Seeking a measure of clinically meaningful change in ALSMartin McElhiney, Judith G Rabkin, Raymond Goetz, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 18, 2015
Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALSRobert G Miller, Gilbert Block, Jonathan S Katz, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 27, 2024
Automated speech analytics in ALS: higher sensitivity of digital articulatory precision over the ALSFRS-RGabriela Stegmann, Chelsea Krantsevich, Julie Liss, et al.
Annals of Neurology|December 19, 2023
Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and PracticeMichael Benatar, Lyle W Ostrow, Joseph W Lewcock, et al.
BMC Neurology|May 31, 2019
Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALSAnne Marie Wills, Jamie Garry, Jane Hubbard, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|December 8, 2009
A phase II trial of talampanel in subjects with amyotrophic lateral sclerosisRobert M Pascuzzi, Jeremy Shefner, Amy S Chappell, et al.
Pageof 16